Brenda Mann's most recent trade in Kiora Pharmaceuticals Inc was a trade of 62 Common Stock done at an average price of $2.0 . Disclosure was reported to the exchange on Nov. 2, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kiora Pharmaceuticals Inc | Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.98 per share. | 02 Nov 2021 | 62 | 15,136 (0%) | 0% | 2.0 | 123 | Common Stock |
| Kiora Pharmaceuticals Inc | Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.02 per share. | 04 Oct 2021 | 62 | 15,198 (0%) | 0% | 2.0 | 125 | Common Stock |
| Kiora Pharmaceuticals Inc | Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.80 per share. | 02 Sep 2021 | 61 | 15,260 (0%) | 0% | 1.8 | 110 | Common Stock |
| Kiora Pharmaceuticals Inc | Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.40 per share. | 03 Aug 2021 | 63 | 15,321 (0%) | 0% | 2.4 | 151 | Common Stock |
| Kiora Pharmaceuticals Inc | Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 02 Jul 2021 | 154 | 15,384 (0%) | 0% | 3.7 | 570 | Common Stock |
| Kiora Pharmaceuticals Inc | Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.19 per share. | 04 Jun 2021 | 155 | 15,538 (0%) | 0% | 4.2 | 649 | Common Stock |
| Kiora Pharmaceuticals Inc | Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.13 per share. | 04 May 2021 | 191 | 15,693 (0%) | 0% | 4.1 | 789 | Common Stock |
| Kiora Pharmaceuticals Inc | Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.94 per share. | 08 Apr 2021 | 192 | 15,884 (0%) | 0% | 4.9 | 948 | Common Stock |
| Kiora Pharmaceuticals Inc | Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.46 per share. | 03 Mar 2021 | 192 | 16,076 (0%) | 0% | 5.5 | 1,048 | Common Stock |
| Kiora Pharmaceuticals Inc | Brenda Mann | VP of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Kiora Pharmaceuticals Inc | Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.34 per share. | 01 Feb 2021 | 988 | 16,268 (0%) | 0% | 6.3 | 6,264 | Common Stock |
| Kiora Pharmaceuticals Inc | Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.85 per share. | 04 Jan 2021 | 115 | 17,256 (0%) | 0% | 4.9 | 558 | Common Stock |
| Kiora Pharmaceuticals Inc | Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.51 per share. | 02 Nov 2020 | 96 | 17,462 (0%) | 0% | 3.5 | 337 | Common Stock |
| Kiora Pharmaceuticals Inc | Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.88 per share. | 02 Oct 2020 | 98 | 17,558 (0%) | 0% | 3.9 | 380 | Common Stock |